Bristol-Myers Squibb (NYSE:BMY) is racing AI-accelerated drug R&D — citing 20–30% faster candidate readiness and a new NVIDIA DGX SuperPOD — while advancing iberdomide toward an Aug. 17 FDA decision that could create the first approved CELMoD, pushing late-stage bispecific tumor programs and stirring takeover talk around Sellas.
Previous Week Recap
- Iberdomide FDA Review Targeted August: Bristol-Myers Squibb's iberdomide, a CELMoD for multiple myeloma, is under FDA review with a target action date of August 17; approval would make it the first FDA-approved CELMoD.
- BMY BioNTech Bispecifics In Trials: Bristol-Myers Squibb (BMY) and BioNTech are advancing bispecific antibody therapies for solid tumors; BMY reports ongoing Phase 3 trials and late-stage clinical activity in the program.
- BMY Linked To Sellas Bid Rumor: Traders flagged Bristol-Myers Squibb (BMY) as a potential bidder for Sellas Life Sciences ahead of Sellas’s Regal AML readout; BMY has made no confirmed bid or announcement.
- AI Advances Drug Trial Readiness: Bristol-Myers Squibb says AI sped drug candidate readiness for trials by 20–30%, with potential to reach 50%. Company credits AI for enabling discovery of an experimental sickle cell program.
- BMY Deploys Large AI Compute: Bristol-Myers Squibb deployed an NVIDIA DGX SuperPOD (Vera Rubin NVL72), its largest in-house AI compute, boosting performance up to 10x per MW to support larger AI workloads across drug R&D areas.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.